Ocuphire Pharma

We are a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies in refractive and retina disorders. $OCUP

[PCON @PCONews]

Oral APX3330 outperformed placebo in slowing progression of #diabeticretinopathy in the phase 2 ZETA-1 trial, according to results presented by @ocuphire at the virtual Angiogenesis, Exudation and Degeneration 2024 conference. @Healio_OSN

Read more! 👇
https://t.co/8VS4kRG2Ry

[Ocuphire Pharma @ocuphire]

It’s #InternationalWomensDay everyday at Ocuphire. Cheers to a female led company!

https://t.co/KGv99LgXGK

[Dr. Rishi P. Singh MD @drrishisingh]

🙏Fortunate to present the results from the ZETA-1 study by Ocuphire on reducing the progression of diabetic retinopathy👁️with a first in class oral 💊agent. Promising results to help our patients see better.

[Ocuphire Pharma @ocuphire]

https://t.co/QWlqZU6oZC

[Ocuphire Pharma @ocuphire]

Thank you @drrishisingh for presenting at #MaculaSociety2023

#diabeticretinopathy

[Dr. Rishi P. Singh MD @drrishisingh]

🙏Fortunate to present the results from the ZETA-1 study by Ocuphire on reducing the progression of diabetic retinopathy👁️with a first in class oral 💊agent. Promising results to help our patients see better.

[Ocuphire Pharma @ocuphire]

@drrishisingh @CleClinicMD @CleClinicNews @CleveClinicFL @ccmartinhealth @eyewireplus @RetinaToday @Healio_OSN @RetinalPhys @MedscapeEye 🙌🙌🙌

[Ocuphire Pharma @ocuphire]

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings https://t.co/5HYOdx7mzD

[Ocuphire Pharma @ocuphire]

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye... https://t.co/lCsbi22HLN

[BioWorld @BioWorld]

After phase II miss, @ocuphire to seek a visual from @US_FDA on next steps in DR https://t.co/yInbdxLvZ6 #biotech #pharma

[Eyewire+ @eyewireplus]

.@ocuphire announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of #diabeticretinopathy (DR). https://t.co/Jci8CuD8wq

[Optometry Times @OptometryTimes]

First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia

More: https://t.co/5hqEMMiFEQ

#Optometry #Presbyopia @ocuphire

[Ocuphire Pharma @ocuphire]

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for... https://t.co/oScNBEpxOt

[Ocuphire Pharma @ocuphire]

Thank you, @OptometryTimes, for the opportunity to share our corporate highlights at the @aaopt meeting in Sunny San Diego! #Presbyopia #reversalofMydriasis #NightVisionDisturbances #diabeticnephropathy @Bindumanne

[Optometry Times @OptometryTimes]

Pipeline update from @ocuphire

More: https://t.co/Ahy3nV22m6

#Optomery #Pipeline

[Optometry Times @OptometryTimes]

First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia

More: https://t.co/OTtmfwFatS

#Optometry #Presbyopia #ClinicalTrial #Clinical @ocuphire

[Ocuphire Pharma @ocuphire]

Join Mina Sooch, CEO, Charlie Hoffmann, VP, Corporate Development and Operations, and the management team at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. #jpm2023 $OCUP #jpm23

Reach out to Investor Relations at [email protected] to connect.

[Ocuphire Pharma @ocuphire]

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia https://t.co/X0fXfAKW7g

[Optometry Times @OptometryTimes]

ICYMI: @ocuphire submits new drug application for eye drops for reversal of mydriasis

More: https://t.co/CEnhSNBLTW

#Optometry #Pipeline #Pediatrics

[Eyewire+ @eyewireplus]

.@ocuphire announces the submission of a NDA to the FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the reversal of pharmacologically-induced #mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents, or a combination thereof. https://t.co/mWm10vQD86

[Ocuphire Pharma @ocuphire]

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis https://t.co/82ZF558aR2

[Ocuphire Pharma @ocuphire]

Ocuphire to Present at Five Upcoming Investor/Industry Conferences https://t.co/jDUcO0ynUL